Product Details:
| Minimum Order Quantity | 10000 Month |
| Model Name/Number | Linjas- E 5/10 or 5/25 |
| Color | Silver |
The combination of linagliptin (a DPP-4 inhibitor) and empagliflozin (an SGLT2 inhibitor) offers synergistic benefits for blood sugar control in type 2 diabetes, along with additional advantages:
Enhanced Glycemic Control:
Linagliptin increases active incretin hormones (GLP-1/GIP), stimulating glucose-dependent insulin secretion and reducing glucagon, thereby lowering fasting and postprandial glucose.
Empagliflozin promotes urinary glucose excretion by inhibiting renal glucose reabsorption, reducing hyperglycemia.
Combined effect: Greater HbA1c reduction compared to monotherapy, targeting multiple pathways (insulin/glucagon modulation + glucose excretion).
Weight Management:
Empagliflozin induces modest weight loss (~2–3 kg) via caloric excretion, countering linagliptin’s weight-neutral profile. Net effect may favor weight loss or neutrality.
Cardiovascular Benefits:
Empagliflozin demonstrates proven cardiovascular risk reduction, particularly in heart failure hospitalization and cardiovascular death. Linagliptin is neutral, not increasing cardiovascular risk. Ideal for patients with atherosclerotic CVD or heart failure.
Renal Protection:
Empagliflozin slows kidney disease progression (e.g., reduces albuminuria, preserves eGFR). Linagliptin requires no dose adjustment in renal impairment, making the combination safe in chronic kidney disease.
Low Hypoglycemia Risk:
Both drugs have glucose-dependent mechanisms, minimizing hypoglycemia risk—suitable for elderly or high-risk patients.
Metabolic and Hemodynamic Effects:
Empagliflozin lowers blood pressure (osmotic diuresis) and may improve glycemic variability. Linagliptin has no direct hemodynamic effects but complements metabolic control.
Tolerability:
Risks include genital infections (SGLT2 inhibitor-related) and rare DPP-4 inhibitor side effects (e.g., pancreatitis). Combined, they avoid hypoglycemia and significant drug interactions.
Clinical Use:
Recommended for patients inadequately controlled on monotherapy, especially those with CVD, heart failure, or renal disease.
Provides a multifaceted approach to diabetes management, addressing both hyperglycemia and comorbidities.
Monitoring:
Regular assessment of renal function, volume status, and infection risks (e.g., genital hygiene education).
This combination optimizes glycemic, cardiovascular, and renal outcomes while maintaining a favorable safety profile.
Key Monitoring and Precautions:Hydration: Ensure adequate fluid intake to reduce dehydration/UTI risks.
Infection Signs: Monitor for genital/urinary symptoms (redness, pain, discharge).
Renal Function: Check eGFR and volume status regularly.
DKA Awareness: Educate patients on DKA symptoms (nausea, vomiting, abdominal pain, fatigue, rapid breathing).
Pancreatitis: Evaluate persistent severe abdominal pain.
Additional Information:
- Delivery Time: 5 to 6 days
- Packaging Details: 10x10
